SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

NCT ID: NCT04171284

Last Updated: 2024-02-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 188 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-22
• Study Completion Date: 2023-02-23

Brief Summary

This is a phase 3 double-blinded randomized multicenter clinical trial of SCT-I10A or placebo plus docetaxel with previously treated squamous cell non-small cell lung cancer patients. The main endpoint is to compare the overall survival (OS) of these two regimens above.

Detailed Description

In 2015, there were near 787,000 patients diagnosed with lung cancer in China. And in the very same year, 631,000 lung cancer patients died of the disease. Lung cancer still causes most cancer related death in here. Approximately 85% of lung cancer is non-small cell lung cancer (NSCLC) compared with small cell lung cancer (~15%) pathologically. NSCLC include squamous cell NSCLC, adenocarcinoma and large cell carcinoma. Although there are therapies developed to treat the condition, patients with advanced squamous-cell (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options in China. Hence, we developed a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor monoclonal antibody (SCT-I10A) which inhibits the interaction between PD-1 and its ligands results in the reactivation of active T cell and finally leads to caner immunotherapy. We are now carrying out a phase 3 clinical trial to determine whether SCT-I10A plus docetaxel surpass docetaxel monotherapy with previously treated squamous-cell NSCLC patients. As designed in the protocol, 360 eligible subjects would be randomized into two arms in a ratio of 2:1. 240 subjects would be treated with SCT-I10A plus docetaxel in the experimental arm while 120 subjects would be treated with placebo plus docetaxel in the active comparator arm. Both of these arms will be treated with maintenance therapy after planed treatments. Our primary endpoint is overall survival, secondary endpoints are PFS, OSR, ORR, DOR, DCR and other efficacy and safety index.

Conditions

Squamous-cell Non-Small-cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

SCT-I10A plus Docetaxel

SCT-I10A 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W. Maximum of 6 cycles

Group Type: EXPERIMENTAL

SCT-I10

Intervention Type: DRUG

200 mg, Q3W, maximum treatment up to six cycles

Docetaxel

Intervention Type: DRUG

70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles

Placebo puls docetaxel

Placebo 200mg, I.V., Q3W; Docetaxel 70-75 mg per square meters of body surface area,I.V., Q3W Maximum of 6 cycles

Group Type: ACTIVE_COMPARATOR

Docetaxel

Intervention Type: DRUG

70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles

Placebo

Intervention Type: DRUG

200 mg, Q3W, maximum treatment up to six cycles

Maintenance therapy of SCT-I10A

Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: SCT-I10A 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.

Group Type: EXPERIMENTAL

SCT-I10

Intervention Type: DRUG

200 mg, Q3W, maximum treatment up to six cycles

Maintenance therapy of Placebo

Subjects complete 2-6 cycles of combined therapies, when the evaluation result is CR, PR or SD (RECIST 1.1), the subjects will enter maintain therapy: Placebo 200mg, I.V., Q3W, till progression, loss to follow-up, new antineoplastic therapy or intolerable toxicity.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

200 mg, Q3W, maximum treatment up to six cycles

Interventions

SCT-I10

200 mg, Q3W, maximum treatment up to six cycles

Intervention Type: DRUG

Docetaxel

70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles

Intervention Type: DRUG

Placebo

200 mg, Q3W, maximum treatment up to six cycles

Intervention Type: DRUG

Other Intervention Names

human PD-1 monoclonal antibody

Eligibility Criteria

Inclusion Criteria

1. Patients should be voluntarily sign the written informed consent.

2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic squamous NSCLC. Or recurrent squamous NSCLC according UICC/AJCC 8th edition.

3. At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously irradiated could be considered as a target lesion only in the condition that progression occurred at the time of 3 months after the end of radiotherapy.

4. Previously treated with one platinum based regimen (including platinum and endostar regimen) and progression occur during or after treatment or unbearable treatment related adverse events.

5. Progression after EGFR-TKIs in patients with driver gene mutation.

6. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

Exclusion Criteria

1. Patient who is allergic to recombinant humanized PD-1 monoclonal antibody or the components of the drug.

2. Patient who is allergic to taxane.

3. Previously treated with any of the antibodies targeted on PD-1, PD-L1, PD-2, CD137, CTLA-4, T cell, co-stimulation or drugs targeted on the checkpoint signal pathway.

4. Previously treated with docetaxel.

5. The histopathological subtype is not squamous cell non-small cell lung cancer, or squamous cell < 90% in a mixed carcinoma.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sinocelltech Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Han Baohui, M.D.

Role: PRINCIPAL_INVESTIGATOR

Shanghai Chest Hospital

Locations

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Countries

China

References

Han B, Wu L, Yang R, Wu H, Li W, Yu Y, Zhang M, Sun H, Chu T, Zhong F, Fang Y, Wu R, Bian T, Guo X, Sun M, Zhang Y, Liu L, Liu X, Pan Y, Jiang O, Wei Z, Lin H, Guo W, Fang J, Wang J, Ding C, Hu Y, Ye F, Zhuang W, Ye S, Wang L, Huang Z, Liu C, Yang L, Wang J, Xie L. Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial. Transl Lung Cancer Res. 2025 Apr 30;14(4):1231-1241. doi: 10.21037/tlcr-24-1042. Epub 2025 Apr 16.

Reference Type: DERIVED

PMID: 40386729 (View on PubMed)

Other Identifiers

SCT-I10A-D301

Identifier Type: -

Identifier Source: org_study_id